Table 2.

Patient characteristics

Case	Sex	Age (y)	Diagnosis	Prior therapy	Cohort/dose schedule	Total
1	M	72	T-cell large granular lymphocyte leukemia	Three cycles: Cyclophosphamide Vindesine Prednisone IFN; Three cycles: Fludarabine Cyclophosphamide IFN	Cohort 8: day 0, 0.8 mg/kg Weekly	6.4 mg/kg over 8 wk
2	F	65	T-cell large granular lymphocyte leukemia	Cyclosporine Methotrexate	Cohort 9 Day 0, 3.4 mg/kg Weekly	64.6 mg/kg over 19 wk
3	F	58	ATLL Acute subtype	Eight cycles: Cyclophosphamide Doxorubicin Vincristine Prednisone	Cohort 9 Day 0, 3.4 mg/kg Weekly	34 mg/kg over 10 wk
4	F	56	Cutaneous T-cell lymphoma Stage IV	Topical steroids Psoaralen and UV light therapy Local radiation	Cohort 6 Day 0, 0.4 mg/kg Day 1, 1.2 mg/kg Day 3, 1.8 mg/kg Every other week	6.8 mg/kg over 2 wk
Subsequent therapy				Time from start of siplizumab to EBV-LPD (d)	EBV-LPD	Outcome
3 mo cyclosporine				189	Extranodal non-Hodgkin’s lymphoma of gastrointestinal tract Monoclonal process Peak EBV viral load 1,600	Complete remission post-chemotherapy
None				147	Mediastinal adenopathy Unable to determine clonality Peak EBV viral load 910	Complete remission after stopping siplizumab
One cycle: denileukin diftitox				55	Extranodal non-Hodgkin’s lymphoma Monoclonal process EBV viral load unavailable	Death from ATLL progression
Six cycles: romidepsin Two cycles: gemcitabine				309	Extensive adenopathy Polyclonal process Peak EBV viral load 1.4 × 106	Complete remission with rituximab